Overview

Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess, in patients with moderate IDA, the Onset-of-Action of a daily treatment with Tot'Héma®. The onset of action is defined as the time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level.
Phase:
Phase 4
Details
Lead Sponsor:
Laboratoire Innotech International